BioSpace News Archive

Alloy Therapeutics , a biotechnology ecosystem company empowering the global scientific community to make better medicines together, today announced the close of a $75 million Series C financing round. The round was led by 8VC, Presight Capital, and Peter Thiel with participation from new investors

Taiho Oncology, Inc. today announced that Phase 2 clinical data, along with preclinical and Phase 1 clinical data for futibatinib (TAS-120) will be presented during the American Association for Cancer Research (AACR) Annual Meeting 2021 Week 1, taking place virtually from April 10-15, 2021 .

Keohane to spearhead commercialization of BioSkryb’s ResolveDNA TM suite of products for high-quality single-cell whole genome amplification

The Impact Genome Project®, a public-private research initiative, announces the Sentinel Outcomes Initiative, a multi-year effort to track and quantify the unmet critical human needs of all Americans, spanning financial health, social capital, food security, housing, employment, and education.

Health Canada is advising Canadians not to use face masks that contain graphene because there is a potential that they could inhale graphene particles, which may pose health risks.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that its single-source Nanox.ARC digital x-ray technology has received 510(k) clearance from the US Food and Drug Administration (the “FDA”).

eMed™, the architect behind the first BinaxNOW™ at-home COVID-19 test kit, announces the non-prescription home use availability of third-party guided and verified COVID-19 at-home tests for asymptomatic serial testing and screening, with results accepted by many airlines and businesses using the Abbott BinaxNOW™ home test and eMed telehealth services.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 106,000 ordinary shares of Nabriva Therapeutics as an inducement to two newly-hired employees.

Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 142,000 shares of Dynavax common stock as inducements to six newly-hired employees in connection with commencement of employment with the Company.

Cellphire Therapeutics, Inc., the global leader in long-term stabilization and storage of platelets, announced today the close of a $15 million Series A financing round led by Simcah Management.